Novavax (NVAX)

• Market cap: $1.36B
• 1 day: -1.99%
• 5 days: 4.48%
• 1 month: -13.59%
• 3 months: 29.28%
• 6 months: 0.12%
• Year to date: -2.1%
• 1 year: -35.11%
• 5 years: -92.74%
• 10 years: -95.95%
• Sector: Healthcare
• Industry: Biotechnology

About: Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Employees: 1,992

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

60% more repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 50

21% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 43

2% more funds holding

Funds holding: 241 [Q1] → 247 (+6) [Q2]

2% more capital invested

Capital invested by funds: $631M [Q1] → $643M (+$11.2M) [Q2]

0.83% more ownership

Funds ownership: 61.23% [Q1] → 62.06% (+0.83%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

31% less call options, than puts

Call options by funds: $52.9M | Put options by funds: $76.6M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7
• Avg. target: $8.5
• High target: $10

2 analyst ratings

• positive: 1 50%
• neutral: 0 0%
• negative: 1 50%

HC Wainwright & Co. Sean Lee	$10	Buy Assumed	28 Aug 2025
B of A Securities Alec Stranahan	$7	Underperform Downgraded	20 Aug 2025